Moxifloxacina Hikma

Moxifloxacin, the active ingredient in Moxifloxacina Hikma, is a fluoroquinolone presented as an intravenous formulation for hospital use. It treats a range of serious bacterial infections in adult patients, including pneumonia, sinusitis, bronchitis exacerbations, skin infections, and intra‑abdominal infections. GNH USA supplies Moxifloxacina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacina Hikma is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria. - Community‑acquired bacterial pneumonia: achieves rapid bacterial clearance and clinical improvement. - Acute bacterial sinusitis: reduces sinus inflammation and resolves infection. - Acute bacterial exacerbation of chronic bronchitis: improves airflow and decreases bacterial load. - Skin and skin structure infections: eradicates pathogenic organisms in soft‑tissue infections. - Intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic pathogens.

Moxifloxacina Hikma may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery or loose. - Headache: transient and often resolves without intervention. - Dizziness: occasional light‑headed sensation. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema, or bronchospasm. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Hepatic failure: rare but may present with jaundice and elevated bilirubin. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe mucocutaneous reactions.

Before initiating therapy with Moxifloxacina Hikma, consider the following precautions. - Renal impairment: monitor renal function and adjust therapy as needed. - History of tendon disorders: avoid use in patients with prior tendon injury. - QT prolongation risk: obtain baseline ECG and avoid concurrent QT‑prolonging drugs. - Concurrent antacids containing aluminum or magnesium: separate administration by at least 2 hours. - Pregnancy and lactation: use only if potential benefits justify the risks. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacina Hikma can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Antacids with aluminum or magnesium: reduce absorption; separate dosing. - Warfarin: may increase INR and bleeding risk. - QT‑prolonging agents (e.g., quinidine, amiodarone): heighten arrhythmia risk. - Systemic corticosteroids: increase tendon rupture potential. - Theophylline: may raise plasma theophylline concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance central nervous system toxicity. - Oral contraceptives: possible reduction in contraceptive efficacy. - Cyclosporine: may increase cyclosporine levels. - Insulin or oral hypoglycemics: risk of hypoglycemia. - Digoxin: potential for elevated digoxin concentrations.